# MUNDERS (CA 1.1971-70-1

# **SEQUENCE LISTING**

### <110> CENTRO DE INMUNOLOGIA MOLECULAR

5	MATEO DE ACOSTA DEL RIO, Maria Cristina (Applicant only for United States of America) ROQUE NAVARRO, Lourdes Tatiana
	(Applicant only for United States of America)
	MORALES MORALES, Alejo
10	(Applicant only for United States of America)
	PEREZ RODRIGUEZ, Rolando
	(Applicant only for United States of America)
	AYALA AVILA, Marta
	(Applicant only for United States of America)
15	GAVILONDO COWLEY, Jorge Víctor
	(Applicant only for United States of America)
	DUEÑAS PORTO, Marta
	(Applicant only for United States of America)
	BELL GARCIA, Hanssel
20	(Applicant only for United States of America)
	RENGIFO CALZADO, Enrique
	(Applicant only for United States of America)
	IZNAGA ESCOBAR, Normando
	(Applicant only for United States of America)
25	RAMOS ZUZARTE, Mayra
	(Applicant only for United States of America)

<120> ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2.

<130> CIM

<140> PCT/CU00/00004

35

30

<141> 2000-11-16

<160> 14

40 <170> Patentin Ver. 2,0

<210> 1

<211>6

<212> PRT

45 <213> mammalian

<220>

<221> DOMAIN

<222> (1)..(6)

## <223> CDR1 OF THE HEAVY CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT

```
<400> 1
Ser Ala Tyr Asn Trp His
5 1 5
```

```
<210> 2
10 <211> 16
<212> PRT
<213> mammalian
```

<220>

15 <221> DOMAIN

<222> (1)..(16)

<223> CDR2 OF THE HEAVY CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT

<400>2

Tyr lle Ser Tyr Asn Gly Thr Thr Ser Tyr Asn Pro Ser Leu Lys Ser
 5
 10
 15

<210> 3 25 <211> 9 <212> PRT <213> mammalian

<220>

<221> DOMAIN

30 <222> (1)..(9) <223> CDR3 OF THE HEAVY CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT

<400> 3 Asn Asp Glu Arg Ala Trp Phe Ala Tyr

35 1 5

<210>4

<211> 16 <212> PRT

<213> mammalian

<220>

<221> DOMAIN

<222> (1)..(16)

45 <223> CDR1 OF THE LIGHT CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT

<400> 4
Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn
1
5
10
15

50

```
<210>5
     <211>7
     <212> PRT
     <213> mammalian
     <220>
     <221> DOMAIN
     <222> (1)..(7)
     <223> CDR2 OF THE LIGHT CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT
10
     <400> 5
     Leu Val Ser Lys Leu Asp Ser
15
     <210>6
     <211>9
20
     <212> PRT
     <213> mammalian
25
     <220>
     <221> DOMAIN
     <222> (1)..(9)
     <223> CDR3 OF THE LIGHT CHAIN RECOMBINANT ANTIBODY AND scFv FRAGMENT
30
     <400>6
     Trp Gln Gly Thr His Phe Pro His Thr
                    5
35
     <210>7
     <211>30
     <212> PRT
     <213> mammalian
40
     <220>
     <221> DOMAIN
     <222> (1)..(30)
     <223> FR1 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
45
     <400>7
     Asp Val Gin Leu Gin Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gin
                     5
                                     10
                                                     15
```

Thr Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr 20 25 30

```
<210>8
 5
     <211>14
     <212> PRT
     <213> mammalian
     <220>
10
     <221> DOMAIN
     <222> (1)..(14)
     <223> FR2 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
     <400>8
15
     Trp lie Arg Gin Phe Pro Gly Lys Gly Leu Glu Trp Met Gly
                    5
       1
     <210>9
     <211> 32
20
     <212> PRT
     <213> mammalian
     <220>
     <221> DOMAIN
25
     <222> (1)..(32)
     <223> FR3 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
     <400>9
     Arg lie Ser lie Thr Arg Asp Thr Ser Lys Asn Gin Phe Phe Leu Gin
30
                   5
                                    10
     Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
                                  25
                 20
35
     <210> 10
     <211> 11
     <212> PRT
     <213> mammalian
40
     <220>
     <221> DOMAIN
     <222> (1)..(11)
     <223> FR4 OF THE HEAVY CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
45
     <400> 10
     Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
                                    10
                    5
50
```

```
<212> PRT
             <213> mammalian
             <220>
             <221> DOMAIN
             <222> (1)..(23)
        10
             <223> FR1 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
             <400> 11
             Asp Trp Trp Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Leu Gly
        15
THE CHANGE TO THE THE
             Gln Pro Ala Ser Ile Ser Cys
                        20
        20
             <210> 12
             <211> 15
             <212> PRT
<213> mammalian
        25
<220>
             <221> DOMAIN
             <222> (1)..(15)
             <223> FR2 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
1
       30
             <400> 12
             Trp Leu Leu Gin Arg Pro Gly Gin Ser Pro Arg Arg Leu lle Tyr
                                              10
        35
             <210> 13
             <211> 32
             <212> PRT
             <213> mammalian
       40
             <220>
             <221> DOMAIN
             <222> (1)..(32)
             <223> FR3 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
```

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ala

<210> 11 <211> 23

<400> 13

# Leu Lys Ile Arg Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 20 25 30

```
5
     <210> 14
     <211> 17
     <212> PRT
     <213> mammalian
10
     <220>
     <221> DOMAIN
     <222> (1)..(17)
     <223> FR4 OF THE LIGHT CHAIN CHIMERIC ANTIBODY AND scFv FRAGMENT
15
     <400> 14
    Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Lys Ser Thr Leu Thr
                                    10
                     5
20
    Gly
```

25

30

35